A Single-Arm, Single Sequence, Multiple Ascending Dose Study of the Safety and Tolerability of AB-2004 in a Pediatric Autism Spectrum Disorder Population
Status: Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 28 Nov 2019
Price : $35 *
At a glance
- Drugs AB 2004 (Primary)
- Indications Pervasive child development disorders
- Focus Adverse reactions
- Sponsors Axial Biotherapeutics
- 27 Nov 2019 Planned number of patients changed from 25 to 35.
- 18 Nov 2019 According to an Axial Biotherapeutics media release, topline data from this trial anticipated in 2020.
- 18 Nov 2019 Status changed from recruiting to active, no longer recruiting, as reported in an Axial Biotherapeutics media release.